imipenem + meropenem + thymosin α1 + ulinastatin

This is a combination therapy consisting of four agents: - **Imipenem** and **meropenem** are carbapenem antibiotics with broad-spectrum activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant strains. Both act by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins, leading to cell lysis and death. Imipenem is generally more active against Gram-positive cocci, while meropenem has greater activity against Gram-negative bacilli[1][2][3][5]. - **Thymosin α1** is a synthetic peptide fragment derived from prothymosin alpha, known for its immunomodulatory properties. It enhances T-cell function and modulates immune responses, often used as an adjunct in infections or cancer therapy (not covered in the search results but widely recognized). - **Ulinastatin** is a protease inhibitor that suppresses inflammatory responses by inhibiting various enzymes such as trypsin, chymotrypsin, elastase, and others. It is used primarily for its anti-inflammatory effects in conditions like acute pancreatitis or sepsis (not covered in the search results but widely recognized). This combination would theoretically provide both potent antibacterial action (from imipenem/meropenem) and immunomodulatory/anti-inflammatory support (from thymosin α1/ulinastatin), potentially useful for severe infections with systemic inflammation.